Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome.

Abstract

Treatment with a single dose of rituximab alone induced remission in a patient with relapsed minimal change nephrotic syndrome (MCNS). A 27-year-old man was given corticosteroid (prednisolone; PSL) and cyclosporine (CyA) therapy combined with rituximab for his fifth relapse in 2008. Thereafter, complete remission was achieved and maintained despite eventual discontinuation of the PSL and CyA. In 2010, we treated his sixth relapse with a single dose of rituximab. Complete remission was obtained 32 days later. This is the first report of rituximab monotherapy in the treatment of MCNS.

• Authors: Nobuyuki Amemiya, Takashi Takei, Chiari Kojima, Hirohiko Nokiba, Mitsuyo Itabashi, Kosaku Nitta
• Journal: Clinical and experimental nephrology (Clin Exp Nephrol) Vol. 15 Issue 6 Pg. 933-6 (Dec 2011) ISSN: 1437-7799 [Electronic] Japan
• PMID: 21823044 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adrenal Cortex Hormones
• Antibodies, Monoclonal, Murine-Derived
• Immunologic Factors
• Immunosuppressive Agents
• Rituximab
• Cyclosporine
• Prednisolone

Topics

• Adrenal Cortex Hormones (therapeutic use)
• Adult
• Antibodies, Monoclonal, Murine-Derived (administration & dosage)
• Cyclosporine (therapeutic use)
• Humans
• Immunologic Factors (administration & dosage)
• Immunosuppressive Agents (therapeutic use)
• Male
• Nephrosis, Lipoid (diagnosis, drug therapy)
• Prednisolone (therapeutic use)
• Recurrence
• Remission Induction
• Rituximab
• Time Factors
• Treatment Outcome